Intraoperative characteristics of somatotropinomas
https://doi.org/10.17650/1683-3295-2023-25-1-36-46
Abstract
Background. Acromegaly is a rare disease associated with insulin‑like growth factor 1 hyperproduction due to the presence of pituitary adenoma in the patient. The first‑line treatment of such patients is surgical removal of the formation in order to normalize hormonal status. The main predictors of the ineffectiveness of surgical treatment and relapse of the disease are large tumor size, tumor invasion into the cavernous sinus, and high preoperative levels of growth hormone, as well as Ki‑6 % expression. The search for additional risk factors for disease recurrence, which according to various sources is approximately 30 % after primary surgical treatment, is an urgent task for researchers. In our work, we studied the intraoperative characteristics of the tumor, size of pituitary adenomas according to preoperative magnetic resonance imaging of the brain, degree of invasion of the tumor into the cavernous sinus according to the Knosp classification and compared them with disease outcomes after a year of follow‑up after surgical treatment.
Aim. To identify new markers of aggressive progression of pituitary tumors.
Materials and methods. A retrospective analysis of medical documentation, protocols of operations of 90 patients aged between 19 and 73 years with the diagnosis of growth hormone‑secreting pituitary adenoma was performed. The dia gnosis was confirmed based on clinical picture, laboratory and instrumental examination methods. All patients underwent endoscopic transsphenoidal removal of pituitary adenoma by one surgeon in one medical institution between 2017 and 2019.
Results. Intraoperative characteristics of the tumor, such as the color of the solid component, density, degree of vascularization were compared with the results of laboratory and instrumental data, as well as the results of surgical treatment after a year of follow‑up.
Conclusion. Such intraoperative characteristics of growth hormone‑secreting pituitary adenomas as the purplish‑gray color of the solid component, high vascularization, as well as dense‑elastic consistency of the tumor, can be considered high risk factors for continued tumor growth in the first 6 months after surgical treatment or relapse of the disease during a year of follow‑up.
About the Authors
R. V. Pletnev
Acad. I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
Roman Vladimirovich Pletnev
6–8 Lva Tolstogo St., Saint Petersburg 197022
V. Yu. Cherebillo
Acad. I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
6–8 Lva Tolstogo St., Saint Petersburg 197022
A. S. Shatilova
Acad. I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
6–8 Lva Tolstogo St., Saint Petersburg 197022
S. A. Bayramova
Acad. I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
6–8 Lva Tolstogo St., Saint Petersburg 197022
References
1. Fleseriu M., Biller B.M.K., Freda P.U. et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021;24(1):1–13. DOI: 10.1007/s11102-020-01091-7
2. Giustina A., Barkhoudarian G., Beckers A. et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 2020;21(4):667–78. DOI: 10.1007/s11154-020-09588-z
3. Rolla M., Jawiarczyk-Przybyłowska A., Halupczok-Żyła J. et al. Complications and comorbidities of acromegaly-retrospective study in Polish Center. Front Endocrinol (Lausanne) 2021;12:642131. DOI: 10.3389/fendo.2021.642131
4. Jung I.H., Choi S., Ku C.R. et al. Revisiting the role of insulin-like growth factor-1 measurement after surgical treatment of acromegaly. J Clin Endocrinol Metab 2021;106(7):e2589–99. DOI: 10.1210/clinem/dgab186
5. Ghajar A., Jones P.S., Guarda F.J. et al. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab 2020;105(3):e532–43. DOI: 10.1210/clinem/dgz187
6. Grigorev A.Yu., Azizyan V.N., Ivashchenko O.V. et al. Results of surgical treatment of somatotropic pituitary adenomas. Endokrinnaya khirurgiya = Endocrine Surgery 2008;2(1):6–9. (In Russ.) DOI: 10.14341/2306-3513-2008-1-6-9
7. Yao S., Chen W.L,. Tavakol S. et al. Predictors of postoperative biochemical remission in acromegaly. J Neurooncol 2021;151(2):313–24. DOI: 10.1007/s11060-020-03669-4
8. Unal T.C., Aydoseli A., Ozgen U. et al. A single-center experience of transsphenoidal endoscopic surgery for acromegaly in 73 patients: results and predictive factors for remission. Br J Neurosurg 2021;1–6:1947977. DOI: 10.1080/02688697.2021.1947977
9. Shen M., Chen Z., Shou X. et al. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly. J Neuroendocrinol 2021;33(5):e12958. DOI: 10.1111/jne.12958.
10. Aydin S., Ozoner B., Sahin S. et al. A follow-up study on outcomes of endoscopic transsphenoidal approach for acromegaly. Clin Neurol Neurosurg 2020;198:106201. DOI: 10.1016/j.clineuro.2020.106201
11. Maia B., Kasuki L., Gadelha M.R. Novel therapies for acromegaly. Endocr Connect 2020;9(12):R274–85. DOI: 10.1530/EC-20-0433
12. Tsiberkin A.I., Tsoy U.A., Cherebillo V.Yu. et al. Evaluation of transsphenoidal adenomectomy outcomes in acromegaly using Р.В. Плетнев: анализ данных, научное редактирование статьи; different remission criteria. Zhurnal voprosy neirokhirurgii im. N.N. Burdenko = Burdenko’s Journal of Neurosurgery 2019;83(1):98–104. (In Russ). DOI: 10.17116/neiro20198301198
13. Swanson A.A., Erickson D., Donegan D.M. et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 2021;24(2):192–206. DOI: 10.1007/s11102-020-01096-2
14. Tsiberkin A.I., Tsoy U.A., Cherebillo V.Yu. et al. Different methods of growth hormone determination in the early postoperative period for prediction of acromegaly recurrence after transsphenoidal adenectomy. Rossiyskiy meditsinskiy zhurnal = Medical Journal of the Russian Federation 2020;26(1):6–9. (In Russ).
15. Agrawal N., Ioachimescu A.G. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary 2020;23(5):582–94. DOI: 10.1007/s11102-020-01063-x
16. Astafeva L.I., Kadashev B.A., Kalinin P.L. et al. Selection of treatment tactics for giant prolactin-secreting pituitary adenomas. Zhurnal voprosy neirokhirurgii im. N.N. Burdenko = Burdenko’s Journal of Neurosurgery 2009;(2):23–8. (In Russ).
Review
For citations:
Pletnev R.V., Cherebillo V.Yu., Shatilova A.S., Bayramova S.A. Intraoperative characteristics of somatotropinomas. Russian journal of neurosurgery. 2023;25(1):36‑46. https://doi.org/10.17650/1683-3295-2023-25-1-36-46
Views:
367
Email this article 